A double-blind study on ulotaront's impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II.

ABSTRACT:

Aims

Antipsychotics increase metabolic syndrome (MetSyn) and diabetes risk. Preclinical and translational research data suggest that ulotaront, an investigational trace amine-associated receptor 1 (TAAR1) agonist, may have beneficial metabolic effects. This Phase 1b study collected pilot data on 4-week ulotaront exposure and weight-associated metabolic markers.

Materials and methods

A double-blind, randomised, multiple-dose within subject trial compared ulotaront to continued prior antipsychotic (PA) on metabolic markers in schizophrenia patients at high diabetes risk (presence of MetSyn and prediabetes). Metabolic characteristics of patients at check-in were compared to a matched historical cohort without schizophrenia or antipsychotic exposure.

Results

When compared

SUBMITTER: Milanovic S 

PROVIDER: S-EPMC12673427 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature